Daphne H Schoenmakers,Sibren van den Berg,Lonneke Timmers,Laura A Adang,Tobias Bäumer,Annet Bosch,Marc van de Casteele,Mareen R Datema,Hanka Dekker,Conan Donnelly,Mariëtte H E Driessens,Holm Graessner,Valerie Greger,Tala Haddad,Günter U Höglinger,Hannerieke van den Hout,Carla Jonker,Mirjam Langeveld,Laurie J Lambert,Eileen Neacy,Marc Nieuwland,Thomas Klockgether,Marjo S van der Knaap,Andri Papadopoulou,Kelly Plueschke,Sanne van Rijn,Noa Rosenberg,Elise F Saunier-Vivar,Bruna Dos Santos Vieira,Carla E M Hollak,Wim G Goettsch,Nicole I Wolf

Abstract:Progress in genetic diagnosis and orphan drug legislation has opened doors to new therapies in rare neurogenetic diseases (RNDs). Innovative therapies such as gene therapy can improve patients' quality of life but come with academic, regulatory, and financial challenges. Registries can play a pivotal role in generating evidence to tackle these, but their development requires multidisciplinary knowledge and expertise. This study aims to develop a practical framework for creating and implementing patient registries addressing common challenges and maximizing their impact on care, research, drug development, and regulatory decision making with a focus on RNDs. A comprehensive 3-step literature and qualitative research approach was used to develop the framework. A qualitative systematic literature review was conducted, extracting guidance and practices leading to the draft framework. Subsequently, we interviewed representatives of 5 established international RND registries to add learnings from hands-on experiences to the framework. Expert input on the draft framework was sought in digital multistakeholder focus groups to refine the framework. The literature search; interviews with 5 registries; and focus groups with patient representatives (n = 4), clinicians (n = 6), regulators, health technology assessment (HTA) bodies and payers (n = 7), industry representatives (n = 7), and data/information technology (IT) specialists (n = 5) informed development of the framework. It covers the interests of different stakeholders, purposes for data utilization, data aspects, IT infrastructure, governance, and financing of rare disease registries. Key principles include that data should be rapidly accessible, independent, and trustworthy. Governance should involve multiple stakeholders. In addition, data should be highly descriptive, machine-readable, and accessible through a shared infrastructure and not spread over multiple isolated repositories. Sustainable and independent financing of registries is deemed important but remains challenging because of a lack of widely supported funding models. The proposed framework will guide stakeholders in establishing or improving rare disease registries that fulfill requirements of academics and patients as well as regulators, HTA bodies, and commercial parties. There is a need for more clarity regarding quality requirements for registries in regulatory and HTA context. In addition, independent financing models for registries should be developed, as well as well-defined policies on technical uniformity in health data.

Scoping review of the recommendations and guidance for improving the quality of rare disease registries

Recommendations for Improving the Quality of Rare Disease Registries

Barriers and facilitators to designing, maintaining, and utilizing rare disease patient registries: a scoping review protocol

Lessons learned from the RE(ACT) conference on medical devices for rare diseases

Establishing Patient Registries for Rare Diseases: Rationale and Challenges

Framework for Multistakeholder Patient Registries in the Field of Rare Diseases: Focus on Neurogenetic Diseases

Informing a national rare disease registry strategy in Australia: a mixed methods study

The EuRRECa Project as a Model for Data Access and Governance Policies for Rare Disease Registries That Collect Clinical Outcomes

Assessing The Practice Of Data Quality Evaluation In A National Clinical Data Research Network Through A Systematic Scoping Review In The Era Of Real-World Data

Needs of people with rare diseases that can be supported by electronic resources: a scoping review

Use cases of registry‐based randomized controlled trials—A review of the registries' contributions and constraints

Prioritization of research engaged with rare disease stakeholders: a systematic review and thematic analysis

Health technology assessment of drugs for rare diseases: insights, trends, and reasons for negative recommendations from the CADTH common drug review

Review of Key Elements in Developing a Common Data Model for Rare Diseases: Identifying Common Success Factors

Application of observational research methods to real-world studies for rare disease drugs: a scoping review protocol

Describing diversity of real world data sources in pharmacoepidemiologic studies: The DIVERSE scoping review

'IRDiRC Recognized Resources': a new mechanism to support scientists to conduct efficient, high-quality research for rare diseases

Use of real‐world evidence in regulatory decisions for rare diseases in the United States—Current status and future directions

Societal Preferences in Health Technology Assessments for Rare Diseases and Orphan Drugs: A Systematic Literature Review of New Analytic Approaches

Increase transparency and reproducibility of real‐world evidence in rare diseases through disease‐specific Federated Data Networks

Lessons from the Rare Diseases Registry and Analytics Platform framework for development of a national rare diseases registry for India